VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
NUTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
NUTXNutex Health, Inc.
$174.51$1.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksNUTXBalance Sheet

Nutex Health, Inc. (NUTX) Balance Sheet

13Y historyFree accessUpdated daily

Total debt of $365.0M against $435.6M of equity yields a 0.67 debt-to-equity ratio, down from 3.80 two years earlier, though absolute debt has remained broadly flat near $340M to $390M, suggesting deleveraging has been driven by equity rebuilding rather than debt repayment.

Income StatementBalance SheetCash FlowRatios

NUTX Balance Sheet

Annual statement

NUTX Balance Sheet

Nutex Health, Inc. (NUTX) balance sheet — 13-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'11Dec'10
Total Current Assets633.24M538.81M292.48M90.85M97.97M154.02M135.51M45.74M305.42K55.08K507.93K7.63M1.76M2.22M
Cash & Short-Term Investments249.91M185.57M43.58M22M34.26M36.12M25.51M8M119.27K9.45K10.52K122.29K224.8K465.55K
Cash Only249.91M185.57M43.58M22M34.26M36.12M25.51M8M119.27K9.45K10.52K122.29K224.8K465.55K
Short-Term Investments00000000000000
Accounts Receivable360.84M325.42M236.05M62.78M58.32M114.76M108.14M36.14M186.15K6.25K15K0720.87K613.65K
Days Sales Outstanding158.38135.71179.5292.5297.06126.34144.04135.9149.798.54--103.24176.87
Inventory5.14M2.87M2.85M3.39M3.53M2.81M1.73M899.91K27.07K00000
Days Inventory Outstanding3.712.433.675.816.336.755.418.1819.45-----
Other Current Assets3.65M24.95M10M2.68M1.87M323.28K00-27.07K39.38K482.41K7.27M754.77K812.73K
Total Non-Current Assets399.13M379.71M362.84M307.4M333.78M240.63M173.05M133.48M144.01K3.27M2.9K3.38K313.77K116.11K
Property, Plant & Equipment361.21M343.9M324.69M269.39M295.15M238.36M170.81M131.28M7.61K3.85K1.18K1.66K18.56K5.09K
Fixed Asset Turnover2.30x2.55x1.48x0.92x0.74x1.39x1.60x0.74x179.58x6.02x--137.30x248.94x
Goodwill13.92M13.92M13.92M17.07M17.01M1.14M1.14M3.47M0000111.03K111.03K
Intangible Assets20.25M21.23M15.53M20.51M21.19M682.65K01.54M2.57M3.27M0000
Long-Term Investments0000000100K116.96K00000
Other Non-Current Assets3.75M662K711.35K431.13K423.43K456.08K1.1M-2.81M19.43K1.95K1.72K1.72K00
Total Assets1.03B918.52M655.32M398.25M431.75M394.65M308.55M179.22M449.43K3.33M510.83K7.64M2.07M2.33M
Asset Turnover0.82x0.95x0.73x0.62x0.51x0.84x0.89x0.54x3.04x0.01x--1.23x0.54x
Asset Growth %87.54%40.16%64.55%-7.76%9.4%27.9%72.16%39778.36%-86.5%551.63%-93.31%268.48%-11.2%-
Total Current Liabilities132.94M157.91M140.87M58.31M54.86M37.69M31.45M72.13M1.04M959.78K6.38M6.08M288.58K351.62K
Accounts Payable10.18M48.97M13.96M25.28M23.93M17.65M8.63M1.75M567.01K348.35K356K168.97K263.19K326.23K
Days Payables Outstanding26.2241.4717.9643.3542.8442.3227.0615.93407.27225.3274.72K93.16K62.81152.04
Short-Term Debt8.17M14.08M17.95M14.18M15.17M10.23M18.65M13.35M477.06K386.19K50K000
Deferred Revenue (Current)00000173.92K38.65K165.56K09.1K0811.23K00
Other Current Liabilities66.79M8.26M005.61M3.6M-38.65K3.37M0216.14K5.97M5.1M25.39K25.39K
Current Ratio4.76x3.41x2.08x1.56x1.79x4.09x4.31x0.63x0.29x0.06x0.08x1.26x6.10x6.31x
Quick Ratio4.72x3.39x2.06x1.50x1.72x4.01x4.25x0.62x0.27x0.06x0.08x1.26x6.10x6.31x
Cash Conversion Cycle135.8796.66165.2254.9960.5590.77122.39128.16-338.12-----
Total Non-Current Liabilities358.52M337.18M312.56M260.83M256.56M165.38M129.73M56.26M902.72K000181.69K0
Long-Term Debt34.2M29.17M22.47M26.31M23.05M78.82M81.9M40.88M902.72K00000
Capital Lease Obligations1.21B298.91M290.1M229.37M223.06M86.56M47.83M15.38M000000
Deferred Tax Liabilities38.91M9.09M05.15M10.45M1.75M00000000
Other Non-Current Liabilities00000-1.75M000000181.69K0
Total Liabilities491.47M495.09M453.43M319.14M311.42M203.07M161.19M128.39M1.95M959.78K6.38M6.08M470.27K351.62K
Total Debt364.98M351.39M340.3M275.76M267.2M178.55M150.12M119.94M1.38M386.19K50K000
Net Debt115.07M165.82M296.72M253.75M232.95M142.43M124.61M111.94M1.26M376.74K39.48K-122.29K-224.8K-465.55K
Debt / Equity0.67x0.83x1.69x3.49x2.22x0.93x1.02x2.36x-0.16x----
Debt / EBITDA1.10x1.19x2.27x--1.00x0.94x3.23x------
Net Debt / EBITDA0.35x0.56x1.98x--0.80x0.78x3.01x------
Interest Coverage16.22x12.01x6.51x-1.97x-32.60x28.35x23.66x10.09x-7.65x-15.35x-173.90x-169.42x--
Total Equity540.91M423.44M201.89M79.11M120.33M191.58M147.37M50.84M-1.5M2.37M-5.87M1.56M1.6M1.99M
Equity Growth %244.63%109.73%155.22%-34.26%-37.19%30%189.89%3495.03%-163.21%140.36%-475.93%-2.58%-19.27%-
Book Value per Share76.8162.6739.5917.9428.4348.4834.3412.28-0.210.57-2.840.761.341.66
Total Shareholders' Equity435.57M329.45M146.34M61.45M95.86M114.65M85.81M28.31M-1.5M2.37M-5.87M1.56M1.6M1.99M
Common Stock7K7K5.51K676.68K650.22K592.79K5.28K4.65K1.77K126.2K39.71K39.68K00
Retained Earnings-133.31M-286.19M-356.89M-409.07M-363.29M102.32M-18.22M-12.57M-5.45M-9.65M-10.23M-2.8M-824.45K-441.06K
Treasury Stock000000000-1M0000
Accumulated OCI00000000000000
Minority Interest105.34M93.99M55.55M17.65M24.46M76.93M61.56M22.53M000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Liquidity Dependence on Working Capital Timing

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Balance Sheet Rebuilt From Equity Deficit

Based on Nutex's reported figures, total equity rose from $60.4M in 2024Q3 to $435.6M in 2026Q3 while accumulated deficit narrowed from -$418.6M to -$133.3M, indicating the balance sheet has strengthened substantially over the period.

The improvement appears driven primarily by retained earnings recovery and the cumulative effect of profitable quarters, rather than external equity infusions that the supplied data does not clearly document. The steady decline in the debt-to-equity ratio from 3.80 to 0.67 suggests the equity base is now carrying a much larger share of the asset structure, which investors should monitor for whether the trend holds through a weaker earnings period.

Leverage Moderated but Debt Remains Material

According to the reported balance sheet, total debt of $365.0M in 2026Q3 against $435.6M of equity yields a 0.67 debt-to-equity ratio, down from 3.80 two years earlier, though absolute debt has remained broadly flat near $340M to $390M.

The reduction in leverage ratio reflects equity growth more than debt repayment, since gross debt has been relatively stable across the ten reported quarters. This suggests the company has not meaningfully deleveraged in absolute terms, so refinancing and interest-coverage risk remain relevant if operating earnings soften. The debt load warrants monitoring alongside the wide gap between operating and net margins in the income statement.

Cash Buffer Strong but Quarterly Volatile

Based on Nutex's reported figures, cash of $249.9M in 2026Q3 against a current ratio of 4.76 indicates ample short-term coverage, though cash has moved between $40.8M and $249.9M across the ten quarters.

The current ratio and cash balance together suggest near-term obligations are well covered, but the sharp swings in cash point to dependence on collection timing rather than a steady liquidity base. Given the working-capital-driven cash swings noted in the cash flow analysis, the current cash position may be less representative of durable liquidity than the headline figure implies.

Asset Base Anchored by Fixed Facilities

As reported in the financial statements, net PP&E of $361.2M represents roughly 36% of total assets of $1.0B in 2026Q3, while goodwill is a minor $13.9M, indicating the asset base is predominantly tangible and facility-linked.

The composition points to a capital-intensive, asset-heavy operating model in which physical hospital infrastructure drives the balance sheet rather than acquired intangibles. The low goodwill balance reduces impairment risk materially, though the reliance on PP&E means returns depend on sustained facility utilization and on-going capital maintenance.

Deficit Recovery Masks Earnings Dispersion

Based on reported quarterly figures, the rebuilt equity may overstate underlying balance sheet durability, given that net margin has ranged widely and the 2026Q3 operating margin of 35.4% compares with a net margin of 18.5%.

The most material distortion is that equity recovery depends on earnings that have proven uneven, so a single weak quarter could reverse part of the accumulated deficit improvement. Investors should monitor whether the balance sheet strength reflects sustained earnings power or a favorable run of collections that may not persist.

NUTX — Frequently Asked Questions

Quick answers to the most common questions about buying NUTX stock.

What are the total assets of Nutex Health, Inc. (NUTX)?

As of 2025, Nutex Health, Inc. (NUTX) had total assets of $918.5M including $538.8M in current assets.

How much debt does Nutex Health, Inc. (NUTX) have?

Nutex Health, Inc. (NUTX) carries total debt of $351.4M, offset by $185.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Nutex Health, Inc.?

Nutex Health, Inc. (NUTX) has total shareholders' equity (book value) of $329.4M ($62.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Nutex Health, Inc.'s current ratio and liquidity?

Nutex Health, Inc. (NUTX) reported a current ratio of 3.41x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.